Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Sanaria Inc. clinical trials
The registry lists 29 studies whose lead sponsor is Sanaria Inc.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 31, 2026.
Keep track of what changes. Save the Sanaria Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sanaria Inc..
- Sanaria Inc.29 studiesSame company
Something wrong?
Focus areas
Conditions Sanaria Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Challenge Trial of PfSPZ-LARC2 Vaccine in Burkina FasoNot yet recruitingNCT07730177Phase 1
- PfSPZ-LARC2 Vaccine in Women of Child-bearing Potential (WOCBP) in MaliRecruitingNCT07675785Phase 2
- Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve AdultsRecruitingNCT06862453Phase 1
- Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe AdultsRecruitingNCT07385287Phase 2
- Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted MalariaCompletedNCT03503058Phase 2
- Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina FasoCompletedNCT06652737Phase 1
- A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMITerminatedNCT05604521Phase 1
- PfSPZ Vaccine Trial in Malian ChildrenCompletedNCT04940130Phase 2
- Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve AdultsCompletedNCT04966871Phase 1
- Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese ChildrenCompletedNCT03521973Phase 2
- Regimen Optimization Trial of PfSPZ Vaccine in Equatorial GuineaCompletedNCT03590340Phase 1
- Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in KenyaCompletedNCT02687373Phase 1/2
- Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian AdultsCompletedNCT03420053Phase 1
- Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch VolunteersCompletedNCT03163121Phase 1
- Sequential Optimization of Dose and Schedule of PfSPZ VaccineCompletedNCT02704533Phase 1
- PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve AdultsCompletedNCT02601716Phase 2
- Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and InfantsCompletedNCT02613520Phase 1
- Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.CompletedNCT02859350Phase 1
- A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of DosesCompletedNCT02215707Phase 1
- Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine ProphylaxisCompletedNCT01728701Phase 1
- Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under ChemoprophylaxisCompletedNCT02115516Phase 1
- Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian AdultsCompletedNCT02132299Phase 1
- Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune AdultsCompletedNCT01771848Phase 1
- Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune AdultsCompletedNCT01624961Phase 1
- Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean AdultsCompletedNCT02418962Phase 1
- Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ ChallengeCompletedNCT02237586Phase 1
- Experimental Human Malaria Infection by PfSPZCompletedNCT01086917Phase 1
- Clinical Trial of the PfSPZ VaccineCompletedNCT01001650Phase 1
- Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian AdultsCompletedNCT01540903Phase 1